Hyperlipidemia: Pharmacotherapy for Cardiovascular Risk Reduction in Adults

Matthew B. Nodelman, MD
Morgan Adams Rhodes, PharmD, BCACP
Charles Carter, MD

American Family Physician. 2026;114(5):484-495.

Author Disclosure: No relevant financial relationships.

This clinical content conforms to AAFP criteria for CME.

Hyperlipidemia management is key to overall cardiovascular risk reduction. Validated risk calculators, including the updated PREVENT​ (Predicting Risk of Cardiovascular Disease Events) equation and Pooled Cohort Equations, should be used to guide lipid-lowering therapy in adults without known atherosclerotic cardiovascular disease (ASCVD). Lipid-lowering medications have shown benefit for primary and secondary prevention of ASCVD, supported by guidelines from the American College of Cardiology/American Heart Association, US Department of Veterans Affairs/US Department of Defense, and the National Institute for Health and Care Excellence. Statins remain first-line agents for primary and secondary prevention, with consistent evidence demonstrating reductions in major adverse cardiovascular events, myocardial infarction, stroke, and all-cause mortality. Statin therapy is recommended for primary prevention in adults 40 to 75 years of age with diabetes, chronic kidney disease stage 3 or higher, or HIV; in patients with low-density lipoprotein cholesterol levels of 190 mg/dL or greater; and in those with elevated 10-year ASCVD risk. Current American College of Cardiology/American Heart Association guidelines expand the recommendation to 30 to 79 years of age. Nonstatin therapies should be considered in patients who cannot tolerate statins or do not achieve adequate low-density lipoprotein cholesterol reduction. Adjunctive therapies may be appropriate for secondary prevention in certain patients. Older adults, younger adults with elevated lifetime risk, and patients of childbearing potential require special considerations. Lipid-lowering therapy should be individualized based on risk assessment, guideline thresholds, and shared decision-making.

RISK CALCULATORS

Management of hyperlipidemia is critical for overall cardiac risk reduction. Risk calculation with validated atherosclerotic cardiovascular disease (ASCVD) tools helps inform lifestyle counseling and treatment decisions. These calculators use patient characteristics to estimate the absolute risk of an ASCVD event and are intended for those without known ASCVD or evidence of subclinical disease (Table 11–5). The 2026 American College of Cardiology/American Heart Association (ACC/AHA) and 2025 US Department of Veterans Affairs/US Department of Defense (VA/DoD) dyslipidemia guidelines and the 2025 ACC/AHA hypertension guidelines recommend assessing ASCVD risk using the newer PREVENT (Predicting Risk of Cardiovascular Disease Events) equation (https://professional.heart.org/en/guidelines-and-statements/prevent-risk-calculator/prevent-calculator).4,6,7

The PREVENT equation calculates 10- and 30-year absolute risk for cardiovascular disease (CVD), ASCVD, and heart failure in adults 30 to 79 years of age. National Institute for Health and Care Excellence guidelines recommend risk assessment with the QRISK3 (QResearch Cardiovascular Risk Algorithm) tool.8 Previously, 2018 ACC/AHA and 2022 US Preventive Services Task Force (USPSTF) guidelines recommended using the Pooled Cohort Equations to assess ASCVD risk.1,9

Notable changes in the PREVENT equation include factors such as removal of race as a category, addition of estimated glomerular filtration rate, and optional variables (eg, zip code to incorporate social drivers of health).2–4,7 Retrospective analysis of National Health and Nutrition Examination Survey data comparing the PREVENT equation with the Pooled Cohort Equations suggests that 81% of treatment recommendations would be similar.5 However, the PREVENT equation identified 18.8% fewer people at increased risk in this study.5 When a treatment recommendation was altered, 75% of patients receiving moderate-intensity therapy were switched to no treatment, and 93% of patients receiving high-intensity therapy changed to moderate-intensity treatment.5 In general, the Pooled Cohort Equations calculator trends toward overestimation of ASCVD risk in the overall population, but the PREVENT equation may underestimate risk in patients not already taking statin therapy.5,10

MATTHEW B. NODELMAN, MD, is the program director at Prisma Health Midlands and a clinical associate professor at the University of South Carolina Floyd School of Medicine Family Medicine Residency Program, Columbia.

MORGAN ADAMS RHODES, PharmD, BCACP, is a clinical associate professor in the Department of Family and Preventive Medicine at the University of South Carolina Floyd School of Medicine, Columbia.

CHARLES CARTER, MD, FAAFP, is a clinical professor in the Department of Family and Preventive Medicine at the University of South Carolina Floyd School of Medicine, Columbia.

See related editorials on pages 449 and 453.

Address correspondence to Matthew B. Nodelman, MD, at matthew.nodelman@prismahealth.org.

Author Disclosure: No relevant financial relationships.

  1. 1.Grundy SM, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143.
  2. 2.Khan SS, et al. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association. Circulation. 2023;148(24):1982-2004.
  3. 3.Khan SS, Matsushita K, Sang Y, et al.; Chronic Kidney Disease Prognosis Consortium and the American Heart Association Cardiovascular-Kidney-Metabolic Science Advisory Group. Development and validation of the American Heart Association's PREVENT equations. Circulation. 2024;149(6):430-449.
  4. 4.Blumenthal RS, et al.; Writing Committee Members. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153(17):e1154-e1276.
  5. 5.Heaton J, et al. Comparison of pooled cohort equation and PREVENT risk calculator for statin treatment allocation. Atherosclerosis. 2024;399:118626.
  6. 6.US Department of Veterans Affairs, US Department of Defense. VA/DoD clinical practice guideline on lipid management for cardiovascular disease risk reduction. 2025. Accessed August 24, 2026. https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/lipids/Lipids-CPG_2025-Guideline_final_20260106.pdf​
  7. 7.Jones DW, et al.; Writing Committee Members. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension. 2025;82(10):e212-e316.
  8. 8.National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. NICE guideline: NG268. December 14, 2023. Accessed August 24, 2026. https://www.nice.org.uk/guidance/ng238​
  9. 9.Mangione CM, et al. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement. JAMA. 2022;328(8):746-753.
  10. 10.Lee MS, et al. PREVENT and PCE models for estimating ASCVD risk stratified by statin exposure. JAMA Netw Open. 2025;8(9):e2532164.
  11. 11.Chou R, et al. Statin use for the primary prevention of cardiovascular disease in adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2022;328(8):754-771.
  12. 12.Grundy SM, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285-e350.
  13. 13.Dugré N, et al. Lipid-lowering therapies for cardiovascular disease prevention and management in primary care: PEER umbrella systematic review of systematic reviews. Can Fam Physician. 2023;69(10):701-711.
  14. 14.Arnett DK, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74(10):e177-e232.
  15. 15.Mach F, et al.; ESC Scientific Document Group. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188.
  16. 16.Mach F, et al.; ESC/EAS Scientific Document Group. 2025 focused update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46(42):4359-4378.
  17. 17.Hippisley-Cox J, et al. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;357:j2099.
  18. 18.Lloyd-Jones DM, et al.; Writing Committee. 2022 ACC Expert Consensus Decision Pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;80(14):1366-1418.
  19. 19.Nissen SE, et al.; CLEAR Outcomes investigators. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388(15):1353-1364.
  20. 20.Nissen SE, et al. Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients. JAMA. 2023;330(2):131-140.
  21. 21.Nexletol [package insert]. Updated June 25, 2026. Accessed August 24, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=88d06d89-a3da-40b4-b273-8f4f7d56c4c9​
  22. 22.Banach M, et al. Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP). Prog Cardiovasc Dis. 2023;79:2-11.
  23. 23.Rao SV, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;151(13):e771-e862.
  24. 24.Lee YJ, et al.; Ez-PAVE investigators. Intensive LDL cholesterol targeting in atherosclerotic cardiovascular disease. N Engl J Med. 2026;394(14):1365-1375.
  25. 25.Zhou Z, et al. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am Heart J. 2006;151(2):273-281.
  26. 26.Baigent C, et al.; Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681.
  27. 27.Baigent C, et al.; Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-1278.
  28. 28.Cheeley MK, et al. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. J Clin Lipidol. 2022;16(4):361-375.
  29. 29.Newman CB, et al.; American Heart Association Clinical Lipidology, Lipoprotein, Metabolism and Thrombosis Committee, a Joint Committee of the Council on Atherosclerosis, Thrombosis and Vascular Biology and Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; Stroke Council. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39(2):e38-e81.
  30. 30.Cannon CP, et al.; IMPROVE-IT investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387-2397.
  31. 31.Zhan S, et al. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Cochrane Database Syst Rev. 2018(11):CD012502.
  32. 32.Du H, et al. Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and meta-analysis. Heart. 2019;105(15):1149-1159.
  33. 33.AlTurki A, et al. Meta-analysis of randomized controlled trials assessing the impact of proprotein convertase subtilisin/kexin type 9 antibodies on mortality and cardiovascular outcomes. Am J Cardiol. 2019;124(12):1869-1875.
  34. 34.UpToDate Lexidrug. Alirocumab. Accessed August 21, 2025. https://online.lexi.com​
  35. 35.UpToDate Lexidrug. Evolocumab. Accessed August 21, 2025. https://online.lexi.com​
  36. 36.Navar AM, et al. CORALreef lipids investigators. A placebo-controlled trial of the oral PCSK9 inhibitor enlicitide. N Engl J Med. 2026;394(6):529-539.
  37. 37.Zhang S, et al. Efficacy and safety of inclisiran versus PCSK9 inhibitor versus statin plus ezetimibe therapy in hyperlipidemia: a systematic review and network meta-analysis. BMC Cardiovasc Disord. 2024;24(1):629.
  38. 38.Cheng Z, et al. Safety and efficacy of inclisiran in treating hypercholesterolemia: a systemic review and meta-analysis. Nutr Metab Cardiovasc Dis. 2025;35(5):103779.
  39. 39.Ray KK, et al.; ORION Phase III investigators. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J. 2023;44(2):129-138.
  40. 40.American Diabetes Association Professional Practice Committee for Diabetes. 10. Cardiovascular disease and risk management: standards of care in diabetes—2026. Diabetes Care. 2026;49:S216-S245.
  41. 41.Bhatt DL, et al.; REDUCE-IT investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22.
  42. 42.Zoungas S, et al.; STAREE investigators. Atorvastatin, cardiovascular events, and disability-free survival in older adults. N Engl J Med. 2026;395(13):1259-1272.
  43. 43.Gencer B, et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020;396(10263):1637-1643.
  44. 44.US Food and Drug Administration. Statins: drug safety communication—FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy. July 20, 2021. Accessed August 24, 2026. https://www.fda.gov/safety/medical-product-safety-information/statins-drug-safety-communication-fda-requests-removal-strongest-warning-against-using-cholesterol​
  45. 45.Last AR, et al. Hyperlipidemia: drugs for cardio vascular risk reduction in adults. Am Fam Physician. 2017;95(2):78-87.
  46. 46.Last AR, et al. Pharmacologic treatment of hyperlipidemia. Am Fam Physician. 2011;84(5):551-558.

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.